Hwang An-Chun, Chen Liang-Yu, Tang Ting-Ching, Peng Li-Ning, Lin Ming-Hsien, Chou Yiing-Jenq, Hsiao Fei-Yuan, Chen Liang-Kung
Center for Geriatrics and Gerontology, Taipei Veterans General Hospital, Taipei, Taiwan; Department of Geriatric Medicine, National Yang Ming Chiao Tung University, School of Medicine, Taipei, Taiwan; Institute of Public Health, National Yang Ming Chiao Tung University, Taipei, Taiwan; Center for Healthy Longevity and Aging Sciences, National Yang Ming Chiao Tung University, Taipei, Taiwan.
Center for Geriatrics and Gerontology, Taipei Veterans General Hospital, Taipei, Taiwan; Department of Geriatric Medicine, National Yang Ming Chiao Tung University, School of Medicine, Taipei, Taiwan; Center for Healthy Longevity and Aging Sciences, National Yang Ming Chiao Tung University, Taipei, Taiwan.
J Am Med Dir Assoc. 2023 Jan;24(1):48-56.e5. doi: 10.1016/j.jamda.2022.10.005. Epub 2022 Nov 10.
To explore the associations of (1) the frailty phenotype or frailty index transition with cause-specific mortality, and (2) different combinations of transition in frailty phenotype and frailty index with all-cause mortality.
Retrospective cohort study.
Data from 3529 respondents aged >50 years who completed the 1999 and 2003 surveys of the Taiwan Longitudinal Study on Aging were analyzed.
Cox regression and subdistribution hazard models were constructed to investigate frailty phenotype or frailty index transitions (by categories of frailty phenotype, absolute and percentage changes in frailty index, and combined categories of the 2 measurements) and subsequent 4-year all-cause and cause-specific mortality, respectively.
Among the frailty phenotype transition groups, the improved frailty group had overall mortality risk comparable to that of the maintained robustness/prefrailty group [hazard ratio (HR): 0.9; 95% CI: 0.7-1.2] and lower risk of mortality due to organ failure (HR: 0.4; 95% CI: 0.2-0.8; P = .015), whereas the worsened frailty group had the highest risk of all-cause mortality and death from infection, malignancy, cardiometabolic/cerebrovascular diseases, and other causes (HR: 1.8-3.7; all P < .03). The rapidly increased frailty index group had significantly higher all-cause and every cause-specific mortality than the decreased frailty index group (HR: 1.8-7.7; all P < .05). When frailty phenotype and frailty index transition groups were combined, participants with worsened frailty/rapidly increased frailty index had increased risk under the same frailty index/frailty phenotype transition condition, particularly for large changes in each factor (HR: 1.5-2.2; P < .01 for worsened frailty; 1.7-4.5, P < .03 for rapidly increased frailty index).
We found that considering both frailty phenotype and frailty index provided best mortality prediction. These associations were independent of baseline frailty status and comorbidities. Nevertheless, even capturing transitions in frailty phenotype or frailty index only can provide good mortality prediction, which supported adopting these approaches in different clinical settings.
探讨(1)衰弱表型或衰弱指数转变与特定病因死亡率之间的关联,以及(2)衰弱表型和衰弱指数的不同转变组合与全因死亡率之间的关联。
回顾性队列研究。
分析了来自3529名年龄大于50岁的受访者的数据,这些受访者完成了1999年和2003年台湾纵向老龄化研究的调查。
构建Cox回归模型和亚分布风险模型,分别研究衰弱表型或衰弱指数的转变(按衰弱表型类别、衰弱指数的绝对变化和百分比变化以及两种测量的组合类别)以及随后4年的全因死亡率和特定病因死亡率。
在衰弱表型转变组中,衰弱改善组的总体死亡风险与维持稳健/前期衰弱组相当[风险比(HR):0.9;95%置信区间:0.7 - 1.2],且因器官衰竭导致的死亡风险较低(HR:0.4;95%置信区间:0.2 - 0.8;P = 0.015),而衰弱恶化组的全因死亡率以及因感染、恶性肿瘤、心脏代谢/脑血管疾病和其他原因导致的死亡风险最高(HR:1.8 - 3.7;所有P < 0.03)。衰弱指数快速增加组的全因死亡率和各特定病因死亡率显著高于衰弱指数降低组(HR:1.8 - 7.7;所有P < 0.05)。当将衰弱表型和衰弱指数转变组进行合并时,在相同的衰弱指数/衰弱表型转变条件下,衰弱恶化/衰弱指数快速增加的参与者风险增加,特别是在每个因素变化较大时(HR:1.5 - 2.2;衰弱恶化时P < 0.01;衰弱指数快速增加时1.7 - 4.5,P < 0.03)。
我们发现同时考虑衰弱表型和衰弱指数可提供最佳的死亡预测。这些关联独立于基线衰弱状态和合并症。然而,即使仅捕捉衰弱表型或衰弱指数的转变也能提供良好的死亡预测,这支持在不同临床环境中采用这些方法。